Kurozumi, Sasagu
Kaira, Kyoichi
Matsumoto, Hiroshi
Kurosumi, Masafumi
Yokobori, Takehiko
Kanai, Yoshikatsu
Sekine, Chikako
Honda, Chikako
Katayama, Ayaka
Furuya, Mio
Shiino, Sho
Makiguchi, Takaya
Mongan, Nigel P.
Rakha, Emad A.
Oyama, Tetsunari
Fujii, Takaaki
Shirabe, Ken
Horiguchi, Jun
Article History
Received: 1 August 2021
Accepted: 2 February 2022
First Online: 17 February 2022
Competing interests
: SK has received honoraria from Chugai Pharmaceutical, Ltd., Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., Eli Lilly and Company, MSD K.K., AstraZeneca K.K., and Novartis Japan. KK has received research grants from and is a speaker honorarium for Ono Pharmaceutical Company, Chugai Pharmaceutical, Taiho Pharmaceutical, and AstraZeneca. TY has received research grants from Ono Pharmaceutical Co., Ltd., CHUGAI Pharmaceutical Co., Ltd., and Memolead Co. KS has received research grants from CHUGAI Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., Ltd. The other authors declare that they have no conflicts of interest.